Viva Biotech Buys Back 0.10 Million Shares on 16 June; Cumulative 28.69 Million Shares Repurchased Since Mandate

Bulletin Express06-16

Viva Biotech Holdings announced that it repurchased 100,000 ordinary shares on 16 June 2026 via on-market transactions at HK$1.18 per share, for a total consideration of HK$0.12 million.

Including this latest trade, Viva Biotech has bought back 28.69 million shares since the current mandate was approved on 12 June 2025, equivalent to 1.35% of the company’s issued share capital on the mandate date. The authorisation permits repurchases of up to 212.84 million shares; thus, 13.49% of the mandate has been utilised to date.

All repurchased shares have yet to be cancelled. As a result, the company’s issued share capital remains unchanged at 2.13 billion shares as of 16 June 2026.

The series of buy-backs executed between 8 May and 16 June 2026 were completed at prices ranging from HK$1.14 to HK$1.57 per share, with volumes spanning from 200,500 to 4.16 million shares per day.

Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares following the 16 June transaction, extending up to 16 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154380380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154380380","market":"us","top_or_hot":-1,"title":"Viva Biotech Buys Back 0.10 Million Shares on 16 June; Cumulative 28.69 Million Shares Repurchased Since Mandate","media":"Bulletin Express","content":"<p>Viva Biotech Holdings announced that it repurchased 100,000 ordinary shares on 16 June 2026 via on-market transactions at HK$1.18 per share, for a total consideration of HK$0.12 million.</p>\n<p>Including this latest trade, Viva Biotech has bought back 28.69 million shares since the current mandate was approved on 12 June 2025, equivalent to 1.35% of the company’s issued share capital on the mandate date. The authorisation permits repurchases of up to 212.84 million shares; thus, 13.49% of the mandate has been utilised to date.</p>\n<p>All repurchased shares have yet to be cancelled. As a result, the company’s issued share capital remains unchanged at 2.13 billion shares as of 16 June 2026.</p>\n<p>The series of buy-backs executed between 8 May and 16 June 2026 were completed at prices ranging from HK$1.14 to HK$1.57 per share, with volumes spanning from 200,500 to 4.16 million shares per day.</p>\n<p>Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares following the 16 June transaction, extending up to 16 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech Buys Back 0.10 Million Shares on 16 June; Cumulative 28.69 Million Shares Repurchased Since Mandate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech Buys Back 0.10 Million Shares on 16 June; Cumulative 28.69 Million Shares Repurchased Since Mandate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-16 17:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings announced that it repurchased 100,000 ordinary shares on 16 June 2026 via on-market transactions at HK$1.18 per share, for a total consideration of HK$0.12 million.</p>\n<p>Including this latest trade, Viva Biotech has bought back 28.69 million shares since the current mandate was approved on 12 June 2025, equivalent to 1.35% of the company’s issued share capital on the mandate date. The authorisation permits repurchases of up to 212.84 million shares; thus, 13.49% of the mandate has been utilised to date.</p>\n<p>All repurchased shares have yet to be cancelled. As a result, the company’s issued share capital remains unchanged at 2.13 billion shares as of 16 June 2026.</p>\n<p>The series of buy-backs executed between 8 May and 16 June 2026 were completed at prices ranging from HK$1.14 to HK$1.57 per share, with volumes spanning from 200,500 to 4.16 million shares per day.</p>\n<p>Under Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares following the 16 June transaction, extending up to 16 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1154380380","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154380380","pubTimestamp":1781601671,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings announced that it repurchased 100,000 ordinary shares on 16 June 2026 via on-market transactions at HK$1.18 per share, for a total consideration of HK$0.12 million. Including...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物于6月16日回购10万股；授权以来累计回购2869万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings announced that it repurchased 100,000 ordinary shares on 16 June 2026 via on-market transactions at HK$1.18 per share, for a total consideration of HK$0.12 million.\nIncluding this latest trade, Viva Biotech has bought back 28.69 million shares since the current mandate was approved on 12 June 2025, equivalent to 1.35% of the company’s issued share capital on the mandate date. The authorisation permits repurchases of up to 212.84 million shares; thus, 13.49% of the mandate has been utilised to date.\nAll repurchased shares have yet to be cancelled. As a result, the company’s issued share capital remains unchanged at 2.13 billion shares as of 16 June 2026.\nThe series of buy-backs executed between 8 May and 16 June 2026 were completed at prices ranging from HK$1.14 to HK$1.57 per share, with volumes spanning from 200,500 to 4.16 million shares per day.\nUnder Hong Kong Stock Exchange rules, Viva Biotech is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares following the 16 June transaction, extending up to 16 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154380380","isCrawlerRequest":true}